Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ross A Okimoto

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Cancer Discovery|January 10, 2016
Tracking Down Response and Resistance to TRK InhibitorsRoss A Okimoto, Trever G Bivona
Personalized Medicine|December 16, 2014
Recent advances in personalized lung cancer medicineRoss A Okimoto, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|January 6, 2017
Metastasis: From head to tailRoss A Okimoto, Trever G Bivona
Lung Cancer (Auckland, N.Z.)|February 18, 2017
AXL receptor tyrosine kinase as a therapeutic target in NSCLCRoss A Okimoto, Trever G Bivona
Current Opinion in Hematology|January 22, 2011
Navigating the road toward optimal initial therapy for chronic myeloid leukemiaRoss A Okimoto, Richard A Van Etten
Oncogene|August 4, 2025
The CIC::DUX4 oncoprotein maintains DNA integrity through direct regulation of the catalytic subunit of DNA polymerase epsilon (POLE)Zeinab Kosibaty, Cuyler Luck, Ross A Okimoto
Biorxiv : the Preprint Server for Biology|June 19, 2024
The <i>Capicua</i> C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion OncoproteinCuyler Luck, Kyle A Jacobs, Ross A Okimoto
Cancer Research Communications|November 12, 2024
The Capicua C1 Domain Is Required for Full Activity of the CIC::DUX4 Fusion OncoproteinCuyler Luck, Kyle A Jacobs, Ross A Okimoto
Brain Pathology (Zurich, Switzerland)|December 19, 2014
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL)Ross A Okimoto, Arie Perry, James L Rubenstein
Frontiers in Cell and Developmental Biology|June 17, 2024
Molecular and therapeutic advancements in Capicua (<i>CIC</i>)-rearranged sarcomaRovingaile Kriska M Ponce, Cuyler Luck, Ross A Okimoto
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Cancer Discovery|January 10, 2016
Tracking Down Response and Resistance to TRK InhibitorsRoss A Okimoto, Trever G Bivona
Personalized Medicine|December 16, 2014
Recent advances in personalized lung cancer medicineRoss A Okimoto, Trever G Bivona
Cell Cycle (Georgetown, Tex.)|January 6, 2017
Metastasis: From head to tailRoss A Okimoto, Trever G Bivona
Lung Cancer (Auckland, N.Z.)|February 18, 2017
AXL receptor tyrosine kinase as a therapeutic target in NSCLCRoss A Okimoto, Trever G Bivona
Current Opinion in Hematology|January 22, 2011
Navigating the road toward optimal initial therapy for chronic myeloid leukemiaRoss A Okimoto, Richard A Van Etten
Oncogene|August 4, 2025
The CIC::DUX4 oncoprotein maintains DNA integrity through direct regulation of the catalytic subunit of DNA polymerase epsilon (POLE)Zeinab Kosibaty, Cuyler Luck, Ross A Okimoto
Biorxiv : the Preprint Server for Biology|June 19, 2024
The <i>Capicua</i> C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion OncoproteinCuyler Luck, Kyle A Jacobs, Ross A Okimoto
Cancer Research Communications|November 12, 2024
The Capicua C1 Domain Is Required for Full Activity of the CIC::DUX4 Fusion OncoproteinCuyler Luck, Kyle A Jacobs, Ross A Okimoto
Brain Pathology (Zurich, Switzerland)|December 19, 2014
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL)Ross A Okimoto, Arie Perry, James L Rubenstein
Frontiers in Cell and Developmental Biology|June 17, 2024
Molecular and therapeutic advancements in Capicua (<i>CIC</i>)-rearranged sarcomaRovingaile Kriska M Ponce, Cuyler Luck, Ross A Okimoto
Pageof 4